Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 677 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single intravenous doses of placebo Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

NCT07504601
View directory record Official record
Conditions
Healthy Volunteers
Interventions
(2R,6R)-Hydroxynorketamine, Placebo
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

NCT02171143
View directory record Official record
Conditions
Rheumatoid Arthritis, Pharmacokinetics of ASP2409
Interventions
ASP2409, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Anniston, Alabama • Costa Mesa, California • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 19, 2026, 10:34 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

NCT07306754
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-243, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Antithrombin (Recombinant), Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Days to 30 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

NCT06148181
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-141, Placebo for ABBV-141
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Tapentadol in Post-Bunionectomy Pain

NCT01435577
View directory record Official record
Conditions
Bunion, Pain
Interventions
Tapentadol, Matching Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

NCT01979601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LGT209, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

NCT05891236
View directory record Official record
Conditions
Malaria
Interventions
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Biological · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional

Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

NCT01001715
View directory record Official record
Conditions
Back Pain
Interventions
REGN475/SAR164877, Placebo (for REGN475/SAR164877)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Beverly Hills, California • Fresno, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

NCT02930018
View directory record Official record
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00103740
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
10
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 19, 2026, 10:34 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

NCT02028403
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-936559, Placebo for BMS-936559
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of SAR440894 vs Placebo

NCT04441905
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Placebo, SAR440894
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Orlando, Florida • Durham, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

NCT04526912
View directory record Official record
Conditions
Acute Lung Injury
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Viela Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

NCT01131000
View directory record Official record
Conditions
Fever
Interventions
Ibuprofen, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

NCT01955707
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 19, 2026, 10:34 AM EDT